Mark Kozloff

9.6k total citations · 1 hit paper
125 papers, 4.7k citations indexed

About

Mark Kozloff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Mark Kozloff has authored 125 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 64 papers in Pulmonary and Respiratory Medicine and 25 papers in Pathology and Forensic Medicine. Recurrent topics in Mark Kozloff's work include Colorectal Cancer Treatments and Studies (39 papers), Lung Cancer Treatments and Mutations (31 papers) and Cancer Treatment and Pharmacology (30 papers). Mark Kozloff is often cited by papers focused on Colorectal Cancer Treatments and Studies (39 papers), Lung Cancer Treatments and Mutations (31 papers) and Cancer Treatment and Pharmacology (30 papers). Mark Kozloff collaborates with scholars based in United States, Spain and United Kingdom. Mark Kozloff's co-authors include Everett E. Vokes, Axel Grothey, Mary M. Sugrue, Wei Dong, David M. Purdie, Daniel J. Sargent, Eric Hedrick, Theodore Karrison, Patrick J. Flynn and Sreenivasa Nattam and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mark Kozloff

122 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

2008 519 citations Axel Grothey, Wei Dong et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark Kozloff	3.2k	1.7k	1.3k	702	612	125	4.7k
M. Mueser	3.8k 1.2×	1.9k 1.1×	795 0.6×	464 0.7×	682 1.1×	18	4.5k
Otilia Dalesio	4.4k 1.4×	3.9k 2.3×	1.5k 1.1×	1.0k 1.5×	1.4k 2.3×	104	8.0k
P. Koralewski	4.5k 1.4×	3.5k 2.1×	2.1k 1.6×	1.7k 2.5×	926 1.5×	58	7.1k
A. Harstrick	5.6k 1.8×	2.9k 1.8×	1.9k 1.5×	702 1.0×	1.8k 2.9×	128	8.2k
Junming Zhu	4.1k 1.3×	4.3k 2.6×	1.8k 1.4×	879 1.3×	941 1.5×	29	7.3k
Dimosthenis Skarlos	4.9k 1.5×	2.1k 1.3×	1.5k 1.1×	873 1.2×	545 0.9×	104	6.4k
Kelly S. Oliner	4.6k 1.5×	2.6k 1.6×	1.3k 1.0×	1.8k 2.5×	1.0k 1.7×	68	6.4k
Karen Borgonovo	2.7k 0.9×	1.5k 0.9×	545 0.4×	639 0.9×	667 1.1×	83	3.8k
Jimmy J. Hwang	2.5k 0.8×	814 0.5×	940 0.7×	637 0.9×	780 1.3×	159	4.2k
Wilfried Eberhardt	4.2k 1.3×	5.3k 3.2×	1.7k 1.3×	892 1.3×	559 0.9×	239	7.6k

Countries citing papers authored by Mark Kozloff

Since Specialization

Citations

This map shows the geographic impact of Mark Kozloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kozloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kozloff more than expected).

Fields of papers citing papers by Mark Kozloff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kozloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kozloff. The network helps show where Mark Kozloff may publish in the future.

Co-authorship network of co-authors of Mark Kozloff

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Kozloff. A scholar is included among the top collaborators of Mark Kozloff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Kozloff. Mark Kozloff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liauw, Stanley L., Tianming Wu, Denise Cloutier, et al.. (2020). A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. Journal of Gastrointestinal Oncology. 11(6). 1399–1407. 9 indexed citations

Melisi, Davide, Rocio García‐Carbonero, Teresa Macarulla, et al.. (2019). TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology. 83(5). 975–991. 77 indexed citations

Rothenstein, J., Alexander I. Spira, Vamsidhar Velcheti, et al.. (2018). P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab. Journal of Thoracic Oncology. 13(10). S495–S495. 3 indexed citations

Marsh, Robert, Marina Talamonti, Marshall S. Baker, et al.. (2017). Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Journal of Surgical Oncology. 117(3). 354–362. 26 indexed citations

Marinis, Filippo de, Fabrice Barlési, Achim Rittmeyer, et al.. (2017). Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study. Annals of Oncology. 28. v467–v467. 2 indexed citations

Miles, David, S. B. Kim, Thierry Velu, et al.. (2016). First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study. Annals of Oncology. 27. vi89–vi89.

Flowers, Christopher R., Mark A. Weiss, Nicole Lamanna, et al.. (2012). PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia. Value in Health. 15(4). A226–A226. 1 indexed citations

Catenacci, Daniel V.T., Mark Kozloff, Hedy L. Kindler, & Blasé N. Polite. (2011). Personalized Colon Cancer Care in 2010. Seminars in Oncology. 38(2). 284–308. 26 indexed citations

Socinski, Mark A., Frank A. Scappaticci, Meghna Samant, Margaret Kolb, & Mark Kozloff. (2010). Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(3). 354–360. 34 indexed citations

10.

Patel, Taral, C. J. Fabian, Mark Kozloff, et al.. (2010). SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Annals of Oncology. 21(12). 2370–2376. 37 indexed citations

11.

Kozloff, Mark, Jordan Berlin, Patrick J. Flynn, et al.. (2010). Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology. 78(5-6). 329–339. 94 indexed citations

12.

Choong, Nicholas W., Mark Kozloff, David Taber, et al.. (2009). Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Investigational New Drugs. 28(5). 677–683. 59 indexed citations

13.

Cohen, Ezra E.W., Darren W. Davis, Theodore Karrison, et al.. (2009). Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. The Lancet Oncology. 10(3). 247–257. 208 indexed citations

14.

Mauer, Ann M., Ezra E.W. Cohen, C. Patrick, et al.. (2008). A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(6). 631–636. 78 indexed citations

15.

Cohen, Roger B., Mark Kozloff, Yazdi K. Pithavala, et al.. (2007). Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors. Molecular Cancer Therapeutics. 6. 1 indexed citations

16.

Choong, Nicholas W., Ann M. Mauer, Eric P. Lester, et al.. (2007). C3-01: Phase I Trial of Erlotinib-based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). S364–S365. 1 indexed citations

17.

Walk, David, et al.. (1998). Mononeuropathy multiplex due to infiltration of lymphoma in hematologic remission. Muscle & Nerve. 21(6). 823–826. 13 indexed citations

18.

Kies, M.S., Daniel J. Haraf, Ilias Athanasiadis, et al.. (1998). Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.. Journal of Clinical Oncology. 16(8). 2715–2721. 75 indexed citations

19.

Vokes, Everett E., Mark J. Ratain, Rosemarie Mick, et al.. (1993). Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.. Journal of Clinical Oncology. 11(2). 360–368. 55 indexed citations

20.

Vokes, Everett E., Richard L. Schilsky, Ralph R. Weichselbaum, Mark Kozloff, & W. R. Panje. (1990). Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.. Journal of Clinical Oncology. 8(2). 241–247. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact